UPSA Delta-Check zone map after radical prostatectomy from Abbott laboratories
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Understanding Your PSA Results After Prostate Surgery
I can see you're looking at PSA delta-check zone mapping from Abbott Diagnostics — this is a sophisticated tool for tracking very small changes in PSA after your radical prostatectomy. Let me break down what this means for your situation.
Your Pathology Stage: pT3a N0 M0
Based on your pathology report, you had locally advanced prostate cancer (the "T3a" means the cancer extended beyond the prostate capsule), but the good news is:
- N0 = No cancer in lymph nodes
- M0 = No distant metastases (spread to other organs)
According to NCCN Guidelines for Patients: Early-Stage Prostate Cancer, after a radical prostatectomy with your stage, your care team will monitor you closely for PSA recurrence through regular PSA testing.
What the Abbott PSA Delta-Check Zone Map Shows
The delta-check (or "change check") is designed to catch meaningful PSA changes while accounting for analytical variability — the natural measurement uncertainty that happens in lab tests.
Why This Matters for You:
At very low PSA levels (<0.01 ng/mL):
- Analytical coefficient of variation (CV) is approximately 15–20%
- This means the lab test itself has built-in variability
- A PSA of 0.005 ng/mL might actually be anywhere from 0.004–0.006 ng/mL due to lab precision limits
The delta-check zone map helps your doctor distinguish:
- ✅ Real PSA changes (true recurrence signal)
- ❌ Lab measurement noise (just normal variability)
What This Means for Your Monitoring
According to NCCN Guidelines, after radical prostatectomy with your stage:
Standard PSA monitoring includes:
- PSA tests every 3–6 months initially (especially important for pT3a)
- If PSA remains undetectable (<0.01 ng/mL), testing may space out to every 6–12 months
- Any rising PSA trend (even small increases) triggers further evaluation
The Abbott delta-check helps your oncologist:
- Identify when a PSA rise is statistically significant (not just lab noise)
- Detect PSA recurrence earlier — when intervention may be most effective
- Avoid unnecessary alarm from minor fluctuations
Key Questions to Ask Your Oncologist
Since you're using this advanced monitoring tool, these questions will help you understand your specific situation:
- "What is my current PSA level, and where does it fall on the delta-check zone map?"
- "How often should I have PSA testing given my pT3a stage?"
- "What PSA level or rate of change would trigger additional imaging or treatment discussion?"
- "Are there any other biomarkers (like PSA doubling time) you're tracking alongside the delta-check?"
- "If my PSA starts rising, what's the next step in evaluation?"
Important Context: PSA After Surgery
According to NCCN Guidelines for Patients: Early-Stage Prostate Cancer, the goal after radical prostatectomy is an undetectable PSA (<0.01 ng/mL).
- PSA persistence = PSA still detectable after surgery (suggests incomplete removal)
- PSA recurrence = PSA drops to undetectable, then rises again (suggests cancer returned)
The delta-check zone map is particularly valuable for detecting early PSA recurrence when PSA is still very low — the window when treatment options may be most effective.
Summary
The Abbott delta-check zone map is a precision tool that helps your care team separate real PSA changes from lab measurement noise. This is especially important at the very low PSA levels you're likely experiencing after surgery.
Your next step: Bring this tool to your next oncology appointment and ask your doctor to explain where your specific PSA values fall on the map and what it means for your monitoring plan.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2
It is h3k27 altered dmg h3k27m negative, egfr a289v myc tp53 mgmt methylated
Your tumor has specific genetic changes H3K27, EGFR, MYC, TP53, MGMT that your doctors will use to guide treatment decisions—these findings help deter